Zacks Research Upgrades Gyre Therapeutics (NASDAQ:GYRE) to “Strong-Buy”

Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a report issued on Tuesday, Zacks reports.

GYRE has been the topic of a number of other research reports. Wall Street Zen upgraded shares of Gyre Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Gyre Therapeutics in a research note on Wednesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy”.

Check Out Our Latest Research Report on GYRE

Gyre Therapeutics Trading Down 4.8%

NASDAQ:GYRE opened at $4.34 on Tuesday. The firm has a market cap of $500.49 million, a price-to-earnings ratio of -21.70 and a beta of 2.14. The company’s 50-day moving average is $6.15 and its two-hundred day moving average is $6.76. Gyre Therapeutics has a 12-month low of $3.97 and a 12-month high of $9.14.

Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.19. The company had revenue of $32.93 million for the quarter, compared to analysts’ expectations of $28.40 million. Gyre Therapeutics had a negative net margin of 14.80% and a negative return on equity of 7.39%. On average, equities research analysts forecast that Gyre Therapeutics will post -0.34 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in GYRE. BlackRock Inc. acquired a new position in shares of Gyre Therapeutics during the second quarter worth about $6,550,000. SBI Securities Co. Ltd. grew its stake in shares of Gyre Therapeutics by 1.8% in the third quarter. SBI Securities Co. Ltd. now owns 169,717 shares of the company’s stock valued at $1,244,000 after buying an additional 2,967 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Gyre Therapeutics in the second quarter valued at about $414,000. Dimensional Fund Advisors LP grew its stake in shares of Gyre Therapeutics by 131.8% in the first quarter. Dimensional Fund Advisors LP now owns 25,268 shares of the company’s stock valued at $176,000 after buying an additional 14,365 shares in the last quarter. Finally, Deutsche Bank AG purchased a new stake in shares of Gyre Therapeutics during the 2nd quarter valued at about $118,000. 23.99% of the stock is owned by hedge funds and other institutional investors.

Gyre Therapeutics Company Profile

(Get Free Report)

Gyre Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for liver and other chronic diseases. The company operates in the United States and China, including through its China-based subsidiary, Beijing Continent Pharmaceuticals. Its pipeline includes hydronidone, also known as F351, an oral drug candidate being developed for liver fibrosis associated with chronic hepatitis B. Gyre is also developing treatments for other serious conditions, including acute-on-chronic liver failure.

Further Reading

Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.